Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $25.48, indicating a -5.56% shift from the previous trading day.

The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result.

Cramer still expects Palantir going to $200. Jim Cramer says no to Viking Therapeutics. Get Discounted Real-Time Trade Alerts For a Volatile Market ( Labor Day Special ) Investor sentiment often swings with the ebb and flow of clinical trial results, technological advancements, and strategic ...